Skip to main content

SARS-CoV Infection

8
Pipeline Programs
10
Companies
8
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
3
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
267%
Small Molecule
133%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

LOSARTAN POTASSIUMApproved
losartan
Unknown Company
oral2023

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
LosartanPhase 4Small Molecule1 trial
Active Trials
NCT04340557Completed31Est. Jun 2020
Novavax
NovavaxMD - Gaithersburg
2 programs
1
1
SARS-CoV-2 rS/Matrix-M1 AdjuvantPhase 31 trial
ICC VaccinePhase 1/2Vaccine1 trial
Active Trials
NCT04961541Completed637Est. Apr 2022
NCT04611802Completed33,000Est. Dec 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
SARS-CoV-2 rS/Matrix-M1 AdjuvantPhase 3
Veru
VeruMIAMI, FL
1 program
1
VERU-111Phase 31 trial
Active Trials
NCT04842747Completed204Est. Jul 2022
SaNOtize
SaNOtizeBC - Vancouver
1 program
1
Nitric Oxide-Releasing DrugPhase 21 trial
Active Trials
NCT04443868Withdrawn0Est. Jul 2021
Bharat Biotech
Bharat BiotechIndia - Hyderabad
1 program
1
BBV154 VaccinePhase 1Vaccine1 trial
Active Trials
NCT04751682Completed175Est. Nov 2021
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
ProbioticsN/A1 trial
Active Trials
NCT04517422Completed300Est. Feb 2021
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
Edoxaban TabletsPHASE_31 trial
Active Trials
NCT04516941Terminated60Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsLosartan
VeruVERU-111
Daiichi SankyoEdoxaban Tablets
NovavaxSARS-CoV-2 rS/Matrix-M1 Adjuvant
SaNOtizeNitric Oxide-Releasing Drug
NovavaxICC Vaccine
Bharat BiotechBBV154 Vaccine
Angeles TherapeuticsProbiotics

Clinical Trials (8)

Total enrollment: 34,407 patients across 8 trials

NCT04340557Sharp TherapeuticsLosartan

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

Start: Mar 2020Est. completion: Jun 202031 patients
Phase 4Completed
NCT04842747VeruVERU-111

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Start: May 2021Est. completion: Jul 2022204 patients
Phase 3Completed
NCT04516941Daiichi SankyoEdoxaban Tablets

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

Start: Jan 2021Est. completion: Aug 202260 patients
Phase 3Terminated
NCT04611802NovavaxSARS-CoV-2 rS/Matrix-M1 Adjuvant

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Start: Dec 2020Est. completion: Dec 202333,000 patients
Phase 3Completed
NCT04443868SaNOtizeNitric Oxide-Releasing Drug

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

Start: Jan 2021Est. completion: Jul 20210
Phase 2Withdrawn
NCT04961541NovavaxICC Vaccine

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Start: Sep 2021Est. completion: Apr 2022637 patients
Phase 1/2Completed
NCT04751682Bharat BiotechBBV154 Vaccine

Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19

Start: Mar 2021Est. completion: Nov 2021175 patients
Phase 1Completed
NCT04517422Angeles TherapeuticsProbiotics

Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19

Start: Aug 2020Est. completion: Feb 2021300 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.